Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

NCT01806649 is registered in ClinicalTrials.gov with Prince of Songkla University as lead sponsor.

NCT NCT01806649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01806649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Lead sponsor
Prince of Songkla University
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2013
Completion date
April 30, 2016
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer